Our Heritage
InferMed was formed in February 1999 by a young management team, backed by Europe's largest independent cancer research organisation, Imperial Cancer Research Fund (now Cancer Research UK) and by Dr. Alan Montgomery, an entrepreneur from the IT industry. Alan had managed the UK R&D Safety Critical Systems project on which a team led by ICRF’s Professor John Fox (now at Oxford University) created the theoretical basis for, and a first prototype of, the technology within Arezzo®. InferMed's mission was to commercialise the results of that research applying the technology in clinical research and clinical practice.
A research relationship continues with Cancer Research UK who remain the largest institutional shareholder. In addition InferMed has worked with commercial partners, notably Hoffman-La Roche, to develop MACROTM, InferMed’s EDC product. MACRO was the first widely distributed application of Arezzo.
Dr Robert Dunlop joined InferMed in July 2000 as Clinical Director, with particular remit to lead research, development and deployment of Arezzo. A large pharmaceutical company became the first customer for an application of Arezzo in the form of RetroGram. InferMed continues to participate actively in European Union R&D projects to help research development of new and existing products.
InferMed has expanded successfully to address the demands of its growing user base and to continue product development. It has focussed on developing and delivering core MACRO and Arezzo software that can be used either directly by customers who want to “own” their key EDC or Clinical Decision Support processes, or embedded in other systems (Arezzo inside General Practice Systems, Hospital Information Systems, patient-facing advice systems) to provide unrivalled user functionality.
InferMed is a committed partner, whether in R&D projects, with global services providers, or with companies who have specialist point of care systems or devices.
|
